CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. (CTMX) Stock Overview
Explore CytomX Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
370.2M
P/E Ratio
4.87
EPS (TTM)
$0.48
ROE
-5.53%
CTMX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of CytomX Therapeutics, Inc. (CTMX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 50.36, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.69.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 4.87 and a market capitalization of 370.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.